secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2023-06-06T23:59:59+00:00
Accession:  0001645113-23-000039
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure LUNAR phase 3 trial meets primary endpoint; median OS improved 3 months in NSCLC
--------------------------------------------------------------------------------

- LUNAR trial met primary endpoint: median OS 13.2 mo (TTFields+SOC) vs 9.9 mo (SOC alone); HR 0.74, p=0.035.
- ICI subgroup showed median OS 18.5 mo (TTFields+ICI) vs 10.8 mo (ICI alone); HR 0.63, p=0.03.
- TTFields therapy well-tolerated with no added systemic toxicities; few grade 3 device-related AEs.
- One-year survival 53% vs 42% (p=0.04); three-year survival 18% vs 7% (p=0.015).
- Novocure plans PMA submission to FDA in H2 2023 based on LUNAR data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000039/0001645113-23-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000039/nvcr-20230606.htm
  HTML page:      https://secwatch.observer/filing/0001645113-23-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer